TuisINDV • NASDAQ
add
Indivior PLC
Vorige sluiting
$11,90
Dagwisseling
$11,58 - $11,92
Jaarwisseling
$7,33 - $18,59
Markkapitalisasie
1,09 mjd GBP
Gemiddelde volume
988,37 k
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
LON
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 266,00 m | -6,34% |
Bedryfskoste | 154,00 m | -10,98% |
Netto inkomste | 47,00 m | 0,00% |
Netto winsgrens | 17,67 | 6,77% |
Wins per aandeel | 0,41 | 10,81% |
EBITDA | 73,00 m | 1,39% |
Effektiewe belastingkoers | 18,97% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 373,00 m | 13,03% |
Totale bates | 1,38 mjd | -5,37% |
Totale aanspreeklikheid | 1,66 mjd | 15,04% |
Totale ekwiteit | -285,00 m | — |
Uitstaande aandele | 125,00 m | — |
Prys om te bespreek | -5,22 | — |
Opbrengs op bates | 11,97% | — |
Opbrengs op kapitaal | 133,86% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | 47,00 m | 0,00% |
Kontant van bedrywe | 75,00 m | 236,36% |
Kontant van beleggings | -5,00 m | -120,00% |
Kontant van finansiering | -17,00 m | 55,26% |
Netto kontantverandering | 53,00 m | 177,94% |
Beskikbare kontantvloei | 98,00 m | 1 145,33% |
Meer oor
Indivior is a specialty pharmaceuticals business. Established as a division of Reckitt Benckiser in 1994 and demerged from that company in December 2014, the company has been fined for false marketing claims about the safety of its drug, Suboxone. It is listed on the London Stock Exchange and on the NASDAQ Global Select Market. Wikipedia
Gestig
26 Sep. 2014
Webwerf
Werknemers
1 041
